NCT01744808View on ClinicalTrials.gov

A Study to Evaluate the Safety, Tolerance, and Pharmacokinetic and Pharmacodynamic Profile Of 1 SR Formulation of EB-1020

PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

February 28, 2014

Study Completion Date

February 28, 2014

Conditions
Normal, Healthy Volunteers
Interventions
DRUG

EB-1020 IR

Immediate release

DRUG

EB-1020 SR1

sustained release

DRUG

EB-1020 SR2

Sustained release

DRUG

EB-1020 SR3

Sustained release

OTHER

Placebo

Placebo formulation

Trial Locations (1)

3004

Nucleus Network Ltd., Melbourne

Sponsors

Lead Sponsor

Neurovance, Inc.
All Listed Sponsors
lead

Neurovance, Inc.

INDUSTRY